Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
I-tech operates in marine technology. The company conducts research and development of substances that inhibit marine fouling on ship hulls. In addition, the products can be used for various marine installations in fish farming and offshore. Customers are found in the marine paint industry and among other players in the shipping industry. I-Tech was founded in 2000 and has its headquarters in Mölndal.
* Q2 organic growth of +91% marks a record quarter * We raise '26e-'28e sales by 7% and EBIT by 23%, 13% & 9% * New aquaculture market entered; EU vote still pending Record quarter, easy comps aside I-Tech delivered very strong Q2 results, with 91% organic...
Sales +21% vs. ABGSCe, EBIT SEK 21m vs. ABGSCe 13m Easy comps, but +91% organic growth still very strong Gross margin held at 59%; raw-material pressure mitigated so far Q2 results I-tech reported very strong Q2 numbers. Sales came in at SEK 59m (+21...
Bliv en del af Inderes community
Gå ikke glip af noget - opret en konto og få alle de mulige fordele
Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
* Q1: Organic growth of +7% despite tough comps (vs. ABGSCe -15%) * Customer with financial constraints back to normal order cadence * We raise organic growth ests. for '26e to +25% (+15% previously) Q1 results Q1 sales were much stronger than we expected...
* Sales +27% vs. ABGSCe, EBIT SEK 19m vs. ABGSCe 9.8m * A beat on all line items, despite very tough comps * Gross margin 60% (56% LY), though may soften on raw material prices Much stronger growth than expected Sales came in above expectations at SEK...
* Approval for Selektope extended again, now until Dec '26 * Ongoing process could not be finalised within timeframe * I-Tech views this as positive; invests in new EOGRT study Approval extended again, until Dec '26 The European Commission and the Standing...